← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 8.5% to $4.1M, while Net income increased 32.7% to ($3.2M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $4.1MWatch
- Profitability — Net income ($3.2M)Watch
- Cash generation — Free cash flow $88.9KOK
- Accounting — Formula distress score · manipulation flag raised · earnings quality safeWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
CHINA PHARMA HOLDINGS, INC.: We, through Helpson, are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China (the "PRC").
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-07-22
- 10-Q · Quarterly report2026-05-15
- 10-K · Annual report2026-04-01
- 8-K · Company announcement2026-03-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CHINA PHARMA HOLDINGS, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.